MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Outlook Arena
- Aug 12, 2015 - GSK Consumer: Favorable cost scenario props up profits...
GSK Consumer: Favorable cost scenario props up profits...
GSK Consumer Healthcare declared results for the quarter ended June 2015. The company's revenues were up by 8% YoY, while profits rose by 19% YoY. Here is our analysis of the results:
Performance summary
- Revenues rise by 8% YoY.
- Operating profits grow by 21% YoY; margins expand by 2% YoY to 19%.
- Net profits expand by 19% YoY led by a strong operating performance.
| (Rs m) | 1QFY15 | 1QFY16 | Change |
| Revenues | 9,660 | 10,450 | 8.2% |
| Expenditure | 8,013 | 8,461 | 5.6% |
| Operating profit (EBITDA) | 1,646 | 1,989 | 20.8% |
| EBITDA margin (%) | 17.0% | 19.0% | |
| Other income | 458 | 549 | 20.0% |
| Depreciation | 119 | 154 | 29.1% |
| Finance cost | 2 | 2 | 10.5% |
| Profit before tax | 1,983 | 2,383 | 20.1% |
| Tax | 682 | 832 | 22.1% |
| Profit after tax/(loss) | 1,301 | 1,550 | 19.1% |
| Net profit margin (%) | 13.5% | 14.8% | |
| No. of shares (m) | 42.1 | 42.1 | |
| Diluted earnings per share (Rs)* | 144.7 | ||
| Price to earnings ratio (x) | 43.4 |
What has driven performance in the quarter ended June 2015?
- GSK's revenues grew by 8% YoY. As per the company, its 'Horlicks' brand gained market share by 1% during the quarter and continued to maintain its leadership position.
- Growth would have been higher had it not been for the phase out of excise duty benefits. The south and east regions remain the key markets for the company with the split being 47% and 37% respectively. Exports formed about 6% of the revenues during the quarter. The north and West markets form about 6% and 4% of sales respectively.
- At the operating level, profits were up by 21% YoY as margins expanded by 2% YoY to 19% led by lower input costs (as a percentage of sales). Net profits grow at similar pace during the quarter.
What to expect?
At the current price of Rs 6,278, GSK trades at a multiple of about 43.4x its trailing twelve month earnings and at about 35x our estimated FY17 EPS.The company continues to largely focus on marketing & expanding its brand extensions as well as expanding its reach across the country. Rural market expansion is a key focus for the company. The company now has over 13,000 sub distributors, which allow it to reach out to over 200,000 touch points across 27,000 villages. The company is looking to expand its distribution reach and hoping to add 1 m outlets to its network in the next year.
As for our view on the stock, we reiterate that it remains overpriced at the current level and that investors should not buy the stock at this juncture.
|
| |
| DISCLOSURES UNDER SEBI (RESEARCH ANALYSTS) REGULATIONS, 2014
|
|
INTRODUCTION:
Equitymaster Agora Research Private Limited (hereinafter referred to as "Equitymaster"/"Company") was incorporated on October 25, 2007. Equitymaster is a joint venture between Quantum Information Services Private Limited (QIS) and Agora group. Equitymaster is a SEBI registered Research Analyst under the SEBI (Research Analysts) Regulations, 2014 with registration number INH000000537. BUSINESS ACTIVITY: An independent research initiative, Equitymaster is committed to providing honest and unbiased views, opinions and recommendations on various investment opportunities across asset classes. DISCIPLINARY HISTORY: There are no outstanding litigations against the Company, it subsidiaries and its Directors. GENERAL TERMS AND CONDITIONS FOR RESEARCH REPORT: For the terms and conditions for research reports click here. DETAILS OF ASSOCIATES: Details of Associates are available here. DISCLOSURE WITH REGARDS TO OWNERSHIP AND MATERIAL CONFLICTS OF INTEREST:
If you have any feedback or query or wish to report a matter, please do not hesitate to write to us. |
GSK CONSUMER SHARE PRICE
Dec 18, 2018 (Close)
TRACK GSK CONSUMER
- Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK CONSUMER
GSK CONSUMER - COCA COLA COMPARISON
COMPARE GSK CONSUMER WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.